Oxaloacetate or oxaloacetic acid (OAA) or Anhydrous Enol-Oxaloacetate or (AEO), also available under the brand name Jubilance, is nutritional supplement currently under investigation as a treatment for chronic fatigue and mental fatigue in ME/CFS and Long COVID. The Jubilance brand has limited evidence that it "may help alleviate the mild to moderate psychological and/or behavioral symptoms associated with Premenstrual Syndrome (PMS)".
Theory[edit | edit source]
Oxaloacetate is produced by the body, and additional oxaloacetate may provide mitochondria support in ME/CFS.
Evidence[edit | edit source]
In 2022, Cash et al. (2022) reported:
- "Anhydrous Enol-Oxaloacetate, (AEO) a nutritional supplement, has been anecdotally reported to relieve physical and mental fatigue and is dimished in ME/CFS patients. Here, we examine the use of higher dosage AEO as a medical food to relieve pathological fatigue."
"76 ME/CFS patients (73.7% women, median age of 47) showed an average reduction in fatigue at 6 weeks as measured by the "Chalder Fatigue Questionnaire" of 22.5% to 27.9% from baseline (P < 0.005) (Likert scoring).
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
Notable studies[edit | edit source]
- 2022, Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial - (Full text)
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- Terra Biological LLC; Bateman Horne Center (February 28, 2022). "A Randomized Double Blind Placebo Controlled Trial to Determine the Effects of Oxaloacetate on Improving Fatigue in ME/CFS". ClinicalTrials.gov. Retrieved August 29, 2022.
- Terra Biological LLC (October 16, 2020). "Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors". clinicaltrials.gov.
- Tully, Lisa; Humiston, John; Cash, Alan (March 2020). "Oxaloacetate reduces emotional symptoms in premenstrual syndrome (PMS): results of a placebo-controlled, cross-over clinical trial". Obstetrics & Gynecology Science. 63 (2): 195–204. doi:10.5468/ogs.2020.63.2.195. ISSN 2287-8572. PMC 7073356. PMID 32206660.
- Cash, Alan; Kaufman, David Lyons (June 28, 2022). "Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial". Journal of Translational Medicine. 20 (1): 295. doi:10.1186/s12967-022-03488-3. ISSN 1479-5876. PMC 9238249. PMID 35764955.
myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.